Abiopharma

🔍 Kim Jae (Executive)

Company: Lumentum Holdings Inc. (LITE)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Sold 205 shares of Common Stock at $842.3932 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 49,599.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 280 shares of Common Stock at $843.6821 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 49,319.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 360 shares of Common Stock at $844.6617 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,959.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 570 shares of Common Stock at $845.959 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,389.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 456 shares of Common Stock at $847.0044 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 47,933.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 491 shares of Common Stock at $847.9411 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 47,442.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 600 shares of Common Stock at $849.1433 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 46,842.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 600 shares of Common Stock at $850.4378 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 46,242.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Sold 970 shares of Common Stock at $851.3098 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 45,272.00 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 1,998 shares of Common Stock at $852.3285 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,274.00 | transaction_form_type: 4 | Footnotes: F1, F11
• Sold 851 shares of Common Stock at $853.5373 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 42,423.00 | transaction_form_type: 4 | Footnotes: F1, F12
• Sold 1,080 shares of Common Stock at $854.8428 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,343.00 | transaction_form_type: 4 | Footnotes: F1, F13
• Sold 273 shares of Common Stock at $855.8929 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,070.00 | transaction_form_type: 4 | Footnotes: F1, F14
• Sold 1,679 shares of Common Stock at $856.698 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 39,391.00 | transaction_form_type: 4 | Footnotes: F1, F15
• Sold 815 shares of Common Stock at $857.9592 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,576.00 | transaction_form_type: 4 | Footnotes: F1, F16
• Sold 40 shares of Common Stock at $858.64 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 38,536.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 732 shares of Common Stock at $860.0367 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,804.00 | transaction_form_type: 4 | Footnotes: F1, F17
• Acquired 1,635 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 39,439.00 | transaction_form_type: 4 | Footnotes: F18

Footnotes:

• F1: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2026.
• F2: These sales were executed in multiple trades at prices ranging from $842.06 to $843.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price, within the ranges set forth in footnotes (2) through (17) to this Form 4, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
• F3: These sales were executed in multiple trades at prices ranging from $843.13 to $843.94.
• F4: These sales were executed in multiple trades at prices ranging from $844.20 to $845.00.
• F5: These sales were executed in multiple trades at prices ranging from $845.41 to $846.33.
• F6: These sales were executed in multiple trades at prices ranging from $846.475 to $847.44.
• F7: These sales were executed in multiple trades at prices ranging from $847.505 to $848.495.
• F8: These sales were executed in multiple trades at prices ranging from $848.51 to $849.495.
• F9: These sales were executed in multiple trades at prices ranging from $849.88 to $850.87.
• F10: These sales were executed in multiple trades at prices ranging from $850.915 to $851.61.
• F11: These sales were executed in multiple trades at prices ranging from $851.935 to $852.87.
• F12: These sales were executed in multiple trades at prices ranging from $853.035 to $854.00.
• F13: These sales were executed in multiple trades at prices ranging from $854.17 to $855.155.
• F14: These sales were executed in multiple trades at prices ranging from $855.17 to $856.15.
• F15: These sales were executed in multiple trades at prices ranging from $856.22 to $857.21.
• F16: These sales were executed in multiple trades at prices ranging from $857.365 to $858.255.
• F17: These sales were executed in multiple trades at prices ranging from $859.99 to $860.69.
• F18: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, following vesting, one share of the Issuer's Common Stock. 1/3 of the shares shall vest one year from the grant date, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter on the 15th of November, February, May and August, subject to the Reporting Person continuing to be an employee through each such date, or as provided under the Issuer's 2025 Equity Incentive Plan.